急性冠脉综合征患者经皮冠状动脉介入治疗后第1个月至第12个月替格瑞洛单药对比替格瑞洛联合阿司匹林(ULTIMATE-DAPT):一项随机、安慰剂对照、双盲临床试验
ULTIMATE-DAPT试验在58个中心纳入完成IVUS-ACS研究且双联抗血小板治疗1个月无事件的急性冠脉综合征患者3400例,随机分配至替格瑞洛联合阿司匹林组或替格瑞洛联合安慰剂组,从经皮冠状动脉介入治疗后1个月至12个月。替格瑞洛单药组临床相关出血发生率低于联合组(2.1% vs 4.6%,HR 0.45),MACCE发生率相似(3.6% vs 3.7%,绝对差异-0.1%),非劣效成立。
要点
- 替格瑞洛单药组临床相关出血发生率为2.1%,替格瑞洛联合阿司匹林组为4.6%(HR 0.45)。
- 替格瑞洛单药组MACCE发生率为3.6%,联合组为3.7%(绝对差异-0.1%,非劣效p<0.0001)。
- 急性冠脉综合征患者经皮冠状动脉介入治疗后双联抗血小板治疗1个月无事件,替格瑞洛单药可降低出血且MACCE不增加。
核心结论
- 急性冠脉综合征患者经皮冠状动脉介入治疗后双联抗血小板治疗1个月无事件,替格瑞洛单药治疗第1个月至第12个月临床相关出血率低于替格瑞洛联合阿司匹林,MACCE发生率相似。
- 结合既往研究,作者认为该人群多数患者可从双联抗血小板治疗1个月后停用阿司匹林并维持替格瑞洛单药治疗中获得更优临床结局。
研究设计与样本
- 随机、安慰剂对照、双盲临床试验,纳入18岁及以上急性冠脉综合征患者,完成IVUS-ACS研究且双联抗血小板治疗1个月无主要缺血或出血事件。
- 共3400例(97.0%)IVUS-ACS研究参与者被随机分配,替格瑞洛联合阿司匹林组1700例,替格瑞洛联合安慰剂组1700例。
- 口服替格瑞洛90 mg每日两次联合口服阿司匹林100 mg每日一次或匹配安慰剂,从经皮冠状动脉介入治疗后1个月至12个月(共11个月)。
- 招募于中国、意大利、巴基斯坦和英国的58个中心进行,随机化采用网络系统,按急性冠脉综合征类型、糖尿病、IVUS-ACS随机化和中心分层,使用动态最小化法。
- 主要优效性终点为临床相关出血(BARC 2、3或5型),主要非劣效性终点为MACCE(心源性死亡、心肌梗死、缺血性卒中、明确支架血栓形成或临床驱动的靶血管血运重建的复合终点),非劣效界值2.5个百分点,所有主要分析在意向治疗人群中进行。
主要发现
- 经皮冠状动脉介入治疗后第1个月至第12个月,替格瑞洛联合安慰剂组临床相关出血35例(2.1%),替格瑞洛联合阿司匹林组78例(4.6%)(HR 0.45 [95% CI 0.30至0.66];p<0.0001)。
- MACCE在替格瑞洛联合安慰剂组61例(3.6%),替格瑞洛联合阿司匹林组63例(3.7%)(绝对差异-0.1% [95% CI -1.4%至1.2%];HR 0.98 [95% CI 0.69至1.39];非劣效p<0.0001,优效性p=0.89)。
- 2019年9月21日至2022年10月27日期间随机分配3400例(97.0%)IVUS-ACS研究参与者,3399例(>99.9%)完成12个月随访。
临床怎么用
- 对于急性冠脉综合征接受当代药物洗脱支架经皮冠状动脉介入治疗且双联抗血小板治疗1个月无事件的患者,作者认为双联抗血小板治疗1个月后停用阿司匹林并维持替格瑞洛单药治疗可使多数患者获得更优临床结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following percutaneous coronary intervention with stent placement to treat acute coronary syndromes, international clinical guidelines generally recommend dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor for 12 months to prevent myocardial infarction and stent thrombosis. However, data on single antiplatelet therapy with a potent P2Y12 inhibitor earlier than 12 months after percutaneous coronary intervention for patients with an acute coronary syndrome are scarce. The aim of this trial was to assess whether the use of ticagrelor alone, compared with ticagrelor plus aspirin, could reduce the incidence of clinically relevant bleeding events without an accompanying increase in major adverse cardiovascular or cerebrovascular events (MACCE). METHODS: In this randomised, placebo-controlled, double-blind clinical trial, patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with dual antiplatelet therapy were randomly assigned to receive oral ticagrelor (90 mg twice daily) plus oral aspirin (100 mg once daily) or oral ticagrelor (90 mg twice daily) plus a matching oral placebo, beginning 1 month and ending at 12 months after percutaneous coronary intervention (11 months in total). Recruitment took place at 58 centres in China, Italy, Pakistan, and the UK. Patients were required to remain event-free for 1 month on dual antiplatelet therapy following percutaneous coronary intervention with contemporary drug-eluting stents. Randomisation was done using a web-based system, stratified by acute coronary syndrome type, diabetes, IVUS-ACS randomisation, and site, using dynamic minimisation. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). The primary non-inferiority endpoint was MACCE (defined as the composite of cardiac death, myocardial infarction, ischaemic stroke, definite stent thrombosis, or clinically driven target vessel revascularisation), with an expected event rate of 6·2% in the ticagrelor plus aspirin group and an absolute non-inferiority margin of 2·5 percentage points between 1 month and 12 months after percutaneous coronary intervention. The two co-primary endpoints were tested sequentially; the primary superiority endpoint had to be met for hypothesis testing of the MACCE outcome to proceed. All principal analyses were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03971500, and is completed. FINDINGS: Between Sept 21, 2019, and Oct 27, 2022, 3400 (97·0%) of the 3505 participants in the IVUS-ACS study were randomly assigned (1700 patients to ticagrelor plus aspirin and 1700 patients to ticagrelor plus placebo). 12-month follow-up was completed by 3399 (>99·9%) patients. Between month 1 and month 12 after percutaneous coronary intervention, clinically relevant bleeding occurred in 35 patients (2·1%) in the ticagrelor plus placebo group and in 78 patients (4·6%) in the ticagrelor plus aspirin group (hazard ratio [HR] 0·45 [95% CI 0·30 to 0·66]; p<0·0001). MACCE occurred in 61 patients (3·6%) in the ticagrelor plus placebo group and in 63 patients (3·7%) in the ticagrelor plus aspirin group (absolute difference -0·1% [95% CI -1·4% to 1·2%]; HR 0·98 [95% CI 0·69 to 1·39]; pnon-inferiority<0·0001, psuperiority=0·89). INTERPRETATION: In patients with an acute coronary syndrome who had percutaneous coronary intervention with contemporary drug-eluting stents and remained event-free for 1 month on dual antiplatelet therapy, treatment with ticagrelor alone between month 1 and month 12 after the intervention resulted in a lower rate of clinically relevant bleeding and a similar rate of MACCE compared with ticagrelor plus aspirin. Along with the results from previous studies, these findings show that most patients in this population can benefit from superior clinical outcomes with aspirin discontinuation and maintenance on ticagrelor monotherapy after 1 month of dual antiplatelet therapy. FUNDING: The Chinese Society of Cardiology, the National Natural Scientific Foundation of China, and the Jiangsu Provincial & Nanjing Municipal Clinical Trial Project. TRANSLATION: For the Mandarin translation of the abstract see Supplementary Materials section.
引用
- Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024. PMID: 38599220. doi:10.1016/S0140-6736(24)00473-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。